Improved laboratory resource utilization and patient care with the use of rapid on-site evaluation for endobronchial ultrasound fine-needle aspiration biopsy

Authors

  • Brian T. Collins MD,

    Corresponding author
    1. Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri
    • Corresponding author: Brian T. Collins, MD, Department of Pathology and Immunology, Washington University in St. Louis, Campus Box 8118, 660 South Euclid Avenue, St. Louis, MO 63110-1093; Fax: (314) 747-2663; bcollins@path.wustl.edu

    Search for more papers by this author
  • Alexander C. Chen MD,

    1. Department of Pulmonary and Critical Care Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri
    Search for more papers by this author
  • Jeff F. Wang MD,

    1. Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri
    Search for more papers by this author
  • Cory T. Bernadt MD, PhD,

    1. Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri
    Search for more papers by this author
  • Souzan Sanati MD

    1. Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri
    Search for more papers by this author

  • We thank Kimberly Green for manuscript assistance.

  • See related editorial on pages 537–9, this issue.

Abstract

BACKGROUND

Endobronchial ultrasound guided (EBUS) fine-needle aspiration (FNA) biopsy has become widely used to evaluate patients with thoracic abnormalities. Rapid on-site evaluation (ROSE) can provide the bronchoscopist with immediate evaluation findings during the procedure. This study examines EBUS FNA biopsy procedures with and without ROSE, and investigates the impact of ROSE service on the EBUS procedure and laboratory resource utilization.

METHODS

The cytopathology database at Washington University Medical Center, St. Louis, Missouri, was searched for EBUS FNA biopsy cases before and after introduction of ROSE service, and a matched cohort was collected. Reports were reviewed and pertinent data was collected, such as sites biopsied, ROSE performance, slide smears, cell blocks, and diagnostic categories. Statistical analysis of the results was performed.

RESULTS

A matched case-controlled EBUS FNA cohort of 340 patients (680 total) for each category of non-ROSE and ROSE service were identified. There was a 33% reduction in the number of sites biopsied with ROSE. A total of 68% of patients with ROSE had just one biopsy site compared to only 36% of non-ROSE patients. There was a 30% decrease in total slides (mean, 5.27 slides) after the introduction of ROSE. All of these improvements were statistically significant.

CONCLUSIONS

EBUS FNA biopsy ROSE service benefits patients by contributing to significantly fewer biopsies and improved utilization of health care resources. ROSE service results in substantially fewer total slides, which has a significant impact on the cytopathology laboratory work effort. The use of ROSE for EBUS FNA biopsy provides significant improvements in patient care and laboratory resource utilization. Cancer (Cancer Cytopathol) 2013;121:544–551. © 2013 American Cancer Society.

Ancillary